<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Ongoing clinical trials with anti-aging drugs and COVID-19. (from ClinicalTrials.gov)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>
     <bold>Intervention / Treatment</bold>
    </th>
    <th>
     <bold>Mechanism of action</bold>
    </th>
    <th>
     <bold>Clinical Trials</bold>
    </th>
    <th/>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Sirolimus</td>
    <td>mTor inhibitor: leads to inhibition of T lymphocyte activation and proliferation; inhibition of antibody production</td>
    <td>Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (SCOPE). Age ≥ 18 years Sirolimus in COVID-19 Phase 1 (SirCO-1). Age: 18–65 years old</td>
    <td>NCT04341675 NCT04371640</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>Sirolimus in COVID-19 Phase 1 (SirCO-1). Age: 18–65 years old</td>
    <td>NCT04371640</td>
   </tr>
   <tr>
    <td>Hydroxychloroquine, Azithromycin, Sirolimus</td>
    <td>Senolytic drug: Hydroxychloroquine alkalinizes the pH in lysosomes, which accumulate in large numbers in senescent cells</td>
    <td>Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients (COVID19-HOPE). Age ≥ 18 years</td>
    <td>NCT04374903</td>
   </tr>
   <tr>
    <td>Quercetin</td>
    <td>Anti-inflammatory agent</td>
    <td>Effect of Quercetin on Prophylaxis and Treatment of COVID-19. Age ≥ 18 years</td>
    <td>NCT04377789</td>
   </tr>
   <tr>
    <td>Hydrocortisone</td>
    <td>Senolytic drug: SASP inhibition</td>
    <td>Hydrocortisone for COVID-19 and Severe Hypoxia (COVID STEROID). Age ≥ 18 years</td>
    <td>NCT04348305</td>
   </tr>
   <tr>
    <td>Ruxolitinib</td>
    <td>Senolytic drug: inhibition of the signalling of cytokines and growth factor receptors that use JAK1 and JAK2 for signalling</td>
    <td>Safety and Efficacy of Ruxolitinib for COVID-19. 18–89 years</td>
    <td>NCT04348071</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS (RuXoCoil). Age ≥ 18 years</td>
    <td>NCT04359290</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection. 12 years and older</td>
    <td>NCT04355793</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation (RuxCoFlam). Age ≥ 18 years</td>
    <td>NCT04338958</td>
   </tr>
   <tr>
    <td>Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin or Tocilizumab</td>
    <td>Combination of senolytic drugs; antiviral; and immunomodulation</td>
    <td>Randomized Evaluation of COVID-19 Therapy (RECOVERY). All ages</td>
    <td>NCT04381936</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
